LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

LLY

996.53

-0.83%↓

JNJ

242.58

-0.54%↓

ABBV

227.52

-0.04%↓

NVS

155.71

-4.3%↓

AZN

193.96

-1.65%↓

Search

ResMed Inc

Atvērts

SektorsVeselības aprūpe

240.25 -3.68

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

236.49

Max

249.67

Galvenie mērījumi

By Trading Economics

Ienākumi

44M

393M

Pārdošana

87M

1.4B

P/E

Sektora vidējais

24.993

66.845

Dividenžu ienesīgums

0.89

Peļņas marža

27.593

Darbinieki

10,600

EBITDA

63M

566M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+18.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.89%

2.25%

Nākamie ieņēmumi

2026. g. 22. apr.

Nākamais dividenžu datums

2026. g. 19. marts

Nākamais Ex dividenžu datums

2026. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-371M

37B

Iepriekšējā atvēršanas cena

243.93

Iepriekšējā slēgšanas cena

240.25

Ziņu noskaņojums

By Acuity

17%

83%

15 / 351 Rangs Healthcare

ResMed Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. marts 20:38 UTC

Peļņas

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

2026. g. 10. marts 23:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 10. marts 23:57 UTC

Tirgus saruna

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

2026. g. 10. marts 23:47 UTC

Tirgus saruna

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

2026. g. 10. marts 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

2026. g. 10. marts 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

2026. g. 10. marts 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

2026. g. 10. marts 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

2026. g. 10. marts 23:35 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

2026. g. 10. marts 23:06 UTC

Peļņas

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

2026. g. 10. marts 22:51 UTC

Galvenie ziņu notikumi

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

2026. g. 10. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

2026. g. 10. marts 21:21 UTC

Peļņas

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

2026. g. 10. marts 21:15 UTC

Peļņas

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

2026. g. 10. marts 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

2026. g. 10. marts 21:14 UTC

Peļņas

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

2026. g. 10. marts 21:13 UTC

Peļņas

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

2026. g. 10. marts 21:12 UTC

Peļņas

Franco-Nevada 4Q Rev $597.3M >FNV

2026. g. 10. marts 21:12 UTC

Peļņas

Franco-Nevada 4Q EPS $1.90

2026. g. 10. marts 20:57 UTC

Peļņas

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026. g. 10. marts 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 10. marts 20:44 UTC

Peļņas

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026. g. 10. marts 20:34 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2026. g. 10. marts 20:34 UTC

Tirgus saruna
Peļņas

Oracle Building More Software for Less Money After Restructuring -- Market Talk

2026. g. 10. marts 20:23 UTC

Peļņas

Oracle Stock Jumps on Earnings Beat -- Barrons.com

2026. g. 10. marts 20:16 UTC

Peļņas

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

2026. g. 10. marts 20:14 UTC

Peļņas

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

2026. g. 10. marts 20:14 UTC

Peļņas

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

2026. g. 10. marts 20:13 UTC

Peļņas

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

2026. g. 10. marts 20:12 UTC

Peļņas

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Salīdzinājums

Cenas izmaiņa

ResMed Inc Prognoze

Cenas mērķis

By TipRanks

18.86% augšup

Prognoze 12 mēnešiem

Vidējais 300.64 USD  18.86%

Augstākais 345 USD

Zemākais 265 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ResMed Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

8

Pirkt

5

Turēt

0

Pārdot

Noskaņojums

By Acuity

15 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat